.png)
.png)
Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the
American Association for Cancer Research (AACR). The data concerns the company’s proprietary
immunomodulatory agent, MDX-124, which has been shown to reduce cancer cell growth by up to 76%
in a broad range of cancer cell lines.
MDX-124 is a humanised monoclonal antibody that specifically targets and inhibits annexin-A1, a protein
that modulates the immune system and plays a key role in the development and spread of many cancers.
In an experimental model of triple negative breast cancer, MDX-124 markedly reduced tumour volume.
Its anti-proliferative effect has also been demonstrated in several cancer cell lines including breast,
colorectal, pancreatic and ovarian cancer. Results suggest that the reduction in cancer cell growth is due
to MDX-124 disrupting the cell cycle phase transition.
Medannex is now preparing to test MDX-124 in a clinical setting for the first time. Medannex Chief
Executive Officer, Ian Abercrombie, said: “The information we are presenting is of great significance to
Medannex as we prepare for initiating our First-in-Human clinical study. MDX-124 has demonstrated
significant potential to impact the treatment of numerous cancers, many of which are poorly responsive
to current immuno-oncology agents.”
The data, co-authored by Medannex and its collaborators at ARU (Cambridge, UK), will be presented at
the AACR Annual Meeting from 22 June 2020. Due to the COVID-19 pandemic, the meeting will be virtual,
and Medannex’s online poster will be accompanied by a recorded audio presentation from the
company’s Director of Scientific Operations, Dr Fiona Dempsey.
American Association for Cancer Research (AACR). The data concerns the company’s proprietary
immunomodulatory agent, MDX-124, which has been shown to reduce cancer cell growth by up to 76%
in a broad range of cancer cell lines.
MDX-124 is a humanised monoclonal antibody that specifically targets and inhibits annexin-A1, a protein
that modulates the immune system and plays a key role in the development and spread of many cancers.
In an experimental model of triple negative breast cancer, MDX-124 markedly reduced tumour volume.
Its anti-proliferative effect has also been demonstrated in several cancer cell lines including breast,
colorectal, pancreatic and ovarian cancer. Results suggest that the reduction in cancer cell growth is due
to MDX-124 disrupting the cell cycle phase transition.
Medannex is now preparing to test MDX-124 in a clinical setting for the first time. Medannex Chief
Executive Officer, Ian Abercrombie, said: “The information we are presenting is of great significance to
Medannex as we prepare for initiating our First-in-Human clinical study. MDX-124 has demonstrated
significant potential to impact the treatment of numerous cancers, many of which are poorly responsive
to current immuno-oncology agents.”
The data, co-authored by Medannex and its collaborators at ARU (Cambridge, UK), will be presented at
the AACR Annual Meeting from 22 June 2020. Due to the COVID-19 pandemic, the meeting will be virtual,
and Medannex’s online poster will be accompanied by a recorded audio presentation from the
company’s Director of Scientific Operations, Dr Fiona Dempsey.